These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26014616)

  • 1. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies.
    Cornejo-Juárez P; Suárez-Cuenca JA; Volkow-Fernández P; Silva-Sánchez J; Barrios-Camacho H; Nájera-León E; Velázquez-Acosta C; Vilar-Compte D
    Support Care Cancer; 2016 Jan; 24(1):253-259. PubMed ID: 26014616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
    Arnan M; Gudiol C; Calatayud L; Liñares J; Dominguez MÁ; Batlle M; Ribera JM; Carratalà J; Gudiol F
    Eur J Clin Microbiol Infect Dis; 2011 Mar; 30(3):355-60. PubMed ID: 21052757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality, hospital length of stay, and recurrent bloodstream infections associated with extended-spectrum beta-lactamase-producing Escherichia coli in a low prevalence region: A 20-year population-based large cohort study.
    Ling W; Paterson DL; Harris PNA; Furuya-Kanamori L; Edwards F; Laupland KB
    Int J Infect Dis; 2024 Jan; 138():84-90. PubMed ID: 37949363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies.
    Cornejo-Juárez P; Pérez-Jiménez C; Silva-Sánchez J; Velázquez-Acosta C; González-Lara F; Reyna-Flores F; Sánchez-Pérez A; Volkow-Fernández P
    PLoS One; 2012; 7(4):e35780. PubMed ID: 22540004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies.
    Vehreschild MJ; Hamprecht A; Peterson L; Schubert S; Häntschel M; Peter S; Schafhausen P; Rohde H; Lilienfeld-Toal MV; Bekeredjian-Ding I; Libam J; Hellmich M; Vehreschild JJ; Cornely OA; Seifert H
    J Antimicrob Chemother; 2014 Dec; 69(12):3387-92. PubMed ID: 25103492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibiotic Resistance and Risk Factors for Mortality of Blood Stream Infections (BSIs) with
    Zhang WL; Huang J; Wu SY; Liu Y; Long F; Xiao YL; Xie Y; He C; Kang M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):133-135. PubMed ID: 29737104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.
    Denis B; Lafaurie M; Donay JL; Fontaine JP; Oksenhendler E; Raffoux E; Hennequin C; Allez M; Socie G; Maziers N; Porcher R; Molina JM
    Int J Infect Dis; 2015 Oct; 39():1-6. PubMed ID: 26189774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonization by fecal extended-spectrum β-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery.
    Golzarri MF; Silva-Sánchez J; Cornejo-Juárez P; Barrios-Camacho H; Chora-Hernández LD; Velázquez-Acosta C; Vilar-Compte D
    Am J Infect Control; 2019 Aug; 47(8):916-921. PubMed ID: 30850249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Patients with Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
    Wang Y; Xiao T; Zhu Y; Ye J; Yang K; Luo Q; Shen P; Xiao Y
    Infect Drug Resist; 2020; 13():3583-3592. PubMed ID: 33116678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.
    Cattaneo C; Di Blasi R; Skert C; Candoni A; Martino B; Di Renzo N; Delia M; Ballanti S; Marchesi F; Mancini V; Orciuolo E; Cesaro S; Prezioso L; Fanci R; Nadali G; Chierichini A; Facchini L; Picardi M; Malagola M; Orlando V; Trecarichi EM; Tumbarello M; Aversa F; Rossi G; Pagano L;
    Ann Hematol; 2018 Sep; 97(9):1717-1726. PubMed ID: 29705860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients.
    Alrstom A; Alsuliman T; Daher N; Abouharb R
    Infect Chemother; 2021 Mar; 53(1):63-74. PubMed ID: 33538132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
    Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study.
    Kömürcü B; Tükenmez Tigen E; Toptaş T; Fıratlı Tuğlular T; Korten V
    Expert Rev Hematol; 2020 Aug; 13(8):923-927. PubMed ID: 32574123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.